What’s in the news from ASCO this year?

So there is no “revolutionary news” in relation to prostate cancer being presented at the annual meeting of the American Society of Medical Oncology (ASCO) in Chicago this year: no results of major phase III trials and no other critical new data that is likely to change physicians’ current practices when they get back home to their clinics. … READ MORE …

Prostate cancer news update, Thursday, September 11

Today’s prostate cancer update includes information on:

  • The lack of any specific connection between prostate cancer risk and a history of sexually transmitted infection
  • A review of current issues in the management of “high risk” prostate cancer patients
  • The effect the Medicare Modernization Action on the use of orchiectomy as compared to LHRH agonist therapy
  • The impact of prostate cancer treatment and outcomes of treatment on couples … READ MORE …

Is a PSM an independent predictor of risk for disease progression?

A study just published by Sæther et al. appears to suggest that the clinical finding of a positive surgical margin (PSM) is not an important independent predictor for risk of progression when compared to other data available at the time of surgery. … READ MORE …

Prostate cancer news update: Tuesday, 9 September

This morning’s news update deals with two newly published studies:

  • The relative effectiveness of two different types of artificial sphincter for the chronically incontinent post-treatment
  • The impact of ADT on metabolic and cardiovascular processes and the risk for significant adverse reactions as a consequence of hypogonadism … READ MORE …

“Entertainment” education about prostate cancer screening

The ability to provide engaging and easily understood information about prostate cancer screening for low literacy popuations is a continuing challenge. Volk et al. have developed and evaluated an “entertainment-based” patient decision aid for prostate cancer screening, comparing its effectiveness among patients with low and high health literacy. … READ MORE …

EBRT for prostate cancer and increased risk for colon cancer?

A recent report by Rapiti et al. from the Geneva Cancer Registry documents a significant increase in risk for colon but not rectum cancer after earlier external beam radiotherapy (EBRT) for prostate cancer. While it is well known that radiotherapy can induce second cancers, there has been some controversy over the risk for second malignancies after irradiation for prostate cancer. … READ MORE …

Blood calcium levels and prostate cancer risk

A Reuters report issued today quotes US-based researchers as saying that men with elevated levels of calcium in their blood may have a much higher risk of getting fatal prostate cancer than the average man with a diagnosis of prostate cancer. … READ MORE …

What’s hot today? Tuesday, September 2

Today’s reports address:

  • The potential prognostic significance of a tertiary Gleason pattern in pathologic analysis of prostate cancer stage following a radical prostatectomy
  • The relative safety of two types of external beam radiotherapy in treatment of patients with localized prostate cancer … READ MORE …

Prostate cancer news update: Monday, September 1

In today’s reports:

  • Zoledronic acid (Zometa) has confirmed it’s impact on skeletal strength in the “real world”
  • Time to recovered of “normal” testosterone levels after ADT has been measured in a prospective clinical trial
  • Acupuncture appear to work to relieve “hot flashes” in men on LHRH agonists … READ MORE …

Cell Genesys halts VITAL-2 GVAX trial

In another severe setback for the application of immunotherapy in the treatment of advanced prostate cancer, Cell Genesys has announced the early termination of the Phase III VITAL-2 clinical trial comparing GVAX + docetaxel to docetaxel + prednisone. … READ MORE …

Two more new drugs enter Phase II trials for androgen-independent prostate cancer

ImClone Systems has announced the initiation of enrollment of patients with androgen-independent prostate cancer (AIPC) in a Phase II clinical trial with either IMC-A12 or IMC-1121B plus mitoxantrone and prednisone. … READ MORE …

Prostate cancer news update: Tuesday, August 26

There are several interesting news items today, as follows:

  • Ethnic variation in the performance of PSA and PSA density as markers for risk of prostate cancer
  • Potential underuse of active surveillance in eligible patients
  • Application of active surveillance in a 40-patient case series
  • The potential to eliminate the need for a urethral (Foley) catheter post-surgery
  • Circulating tumor cell levels as a predictor for response to androgen deprivation therapy … READ MORE …

Obesity, statins, and risk for prostate cancer

A recent epidemiologic study in King County, Washington, has found an increased risk for prostate cancer associated with statin use among obese men. … READ MORE …

Prostate cancer news update: Monday, August 25

Two reports just published would appear to confirm individual patient experiences in the treatment of advanced disease:

  • The impact of ADT on body composition
  • The effects of docetaxel chemotherapy in men aged ≥ 75 years … READ MORE …

Prostate cancer news update: Saturday, August 23

Todays’ reports contain some interesting data, although it is not entirely clear how they should best be applied in the diagnosis and potential management of patients at risk:

  • A study of patient preferences and decision making about how to be treated
  • Why some Brazilian men reject digital rectal examination (fewer that you might expect)
  • The natural history of high-grade prostatic intraepithelial neoplasia (HGPIN)
  • The potential of ferumoxtran-10 (Combidex) in diagnosis of lymph node metastases … READ MORE …